Biomerica 10-K: Going Concern Warning, 300M Authorized Shares, Nasdaq Delisting Risk
BMRA sits 44% above its 52-week low of $1.45.
Summary
Biomerica's 10-K reveals a going concern warning with only $1.3M cash, a 12x increase in authorized shares to 300M, and new Nasdaq delisting risk under the $5M MVLS rule.
Key Events · Earnings and Guidance · BMRA
-
Going Concern Warning Reiterated
Cash of $1.3M is insufficient to fund operations for the next 12 months; auditor includes explanatory paragraph on substantial doubt.
-
Authorized Shares Increased 12x
Common shares authorized increased from 25M to 300M effective June 10, 2026, creating massive potential dilution headroom.
-
Nasdaq Delisting Risk
New $5M MVLS rule approved July 22, 2026 could trigger immediate suspension without cure period if stock price declines.
-
New CFO Appointed
Xiaoxuan Qu appointed Principal Financial Officer and Principal Accounting Officer effective August 27, 2026.
Analysis · BMRA · Life Sciences
Biomerica's annual report confirms the company cannot fund operations for the next 12 months with only $1.3M in cash, while simultaneously revealing a massive authorized share increase from 25M to 300M shares and a new Nasdaq delisting risk under the $5M MVLS rule. The combination of a going concern warning, a 12x increase in authorized shares, and potential delisting creates a critical survival situation for shareholders. The company raised $2.23M in a private placement just days ago, but that only extends the runway marginally. The new CFO appointment and $1.75M CDMO contract are positive but insufficient to offset the existential risks.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRA was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $1.45 to $3.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.